Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

990
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
990
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profilin-1 Deficiency Activates STING to Drive T Cell-Mediated Anti-Tumor Immunity in Breast Cancer.

bioRxiv : the preprint server for biology·2026
Same author

Recent advances in the development of optical chemosensors and chemodosimeters for the recognition of Hg<sup>2</sup>.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Functional regeneration of complex ballistic trauma via herbal extract and antibiotic loaded multilayered nanofibrous hydrogel scaffold.

International journal of biological macromolecules·2026
Same author

Molecular insights into profilin 1-dependent regulation of cellular phosphatidylinositol (4,5)-bisphosphate.

Journal of cell science·2026
Same author

A Divergent MBL-Fold Metallo-Hydrolase (Kmh-1) from <i>Klebsiella pneumoniae</i> Confers Aztreonam Degradation and Expands the β-Lactamase Landscape.

ACS infectious diseases·2026
Same author

Comprehensive scientific insights on plant inspired nano therapeutics as the missing piece of the breast cancer puzzle.

Discover nano·2026

Related Experiment Video

Updated: Apr 27, 2026

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
08:53

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Published on: April 16, 2019

7.3K

Engineered silybin nanoparticles educe efficient control in experimental diabetes.

Suvadra Das1, Partha Roy2, Rajat Pal3

  • 1Department of Chemical Technology, University of Calcutta, Kolkata, West Bengal, India.

Plos One
|July 4, 2014
PubMed
Summary
This summary is machine-generated.

Engineered silybin nanoparticles improve diabetes treatment by enhancing solubility and bioavailability. These nanoparticles restore insulin levels and improve glucose control in diabetic models.

More Related Videos

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates
11:24

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates

Published on: May 14, 2019

5.1K
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.6K

Related Experiment Videos

Last Updated: Apr 27, 2026

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
08:53

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Published on: April 16, 2019

7.3K
Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates
11:24

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates

Published on: May 14, 2019

5.1K
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.6K

Area of Science:

  • Pharmacology
  • Biotechnology
  • Diabetology

Background:

  • Silybin shows therapeutic potential for various diseases, including diabetes.
  • Silybin's clinical use is limited by poor solubility and bioavailability.
  • Nanoparticle formulation offers a strategy to overcome these limitations.

Purpose of the Study:

  • To design and evaluate surface-engineered biopolymeric nanoparticles for improved silybin delivery.
  • To assess the efficacy of silybin nanoparticles in an experimental diabetic model.

Main Methods:

  • Development of surface-engineered biopolymeric nanoparticles with high silybin encapsulation efficiency (92.11%).
  • In vivo evaluation of silybin nanoparticles in streptozotocin-induced diabetic animal models.
  • Assessment of key glycemic control markers, including blood glucose, serum insulin, and glycated hemoglobin.

Main Results:

  • Silybin nanoparticles significantly reduced blood glucose levels to near normal values within 28 days.
  • Nanoparticle treatment led to substantial regeneration of serum insulin levels (from 0.17 to 0.57 µg/lit).
  • Significant reductions in glycated hemoglobin and restoration of liver glycogen content were observed.

Conclusions:

  • Engineered silybin nanoparticles demonstrate significant therapeutic efficacy in managing experimental diabetes.
  • Improved dissolution, nanoscale passive transport, and antioxidant status restoration contribute to the observed benefits.
  • This approach holds promise for overcoming silybin's limitations and enhancing its diabetic treatment potential.